Quartalzahlen bei Stemcells - 500 Beiträge pro Seite

[Dixi1]

Hallo zusammen,

hat jemand von Euch infos wann bei Stemcells die Quartalszahlen veröffentlicht werden?

Gruß Dixi1

[LMeister7]

@ dixi 1
Hallo, unter diesem Link findest Du viele interessante Zahlen über StemCells. Q4-Zahlen gibts laut Forbes am 25. Februar.
HTTP://www.forbes.com/finance/mktguideapps/compinfo/CompanyT…

Schönen Sonntag noch,
LM7

[Dixi1]

World Stem Cell Research Community to Convene At February 25-26 Conference To Assess Scientific and Commercial Opportunities

PRINCETON, N.J., Feb. 5 /PRNewswire/ -- The world industrial stem cell and regenerative medicine communities will convene in Princeton, NJ to assess the most important research advances being developed for novel and regenerative therapeutics at the first such industry conference, announces Strategic Research Institute.

Executives from the stem cell industry`s leading biotech and biopharmaceutical companies will present their most recent data on hESC`s, CNS, pancreatic, bone marrow stem cell transplantation, cell therapy and regenerative medicine/tissue engineering.

Leading companies, including as Geron Corporation, Aastrom Bioscience, Curis, Osiris Therapeutics, StemCells Inc. and Bresagen among others, will discuss their role in the industry to an broad audience comprised of pharmaceutical, academic and biotech researchers, executives and scientists.

The Executive Keynote presentation will be given by Dr. Thomas Okarma, M.D., Ph.D., President and CEO of Geron Corporation.

Following the scientific presentations, an audience interactive panel comprised of venture capitalists and fund managers, expert in the commercial aspects of stem cell research, will discuss financial implications of this promising field as it relates to the pharmaceutical and biotech industries.

[TS80]

Bin heute rein in Stemcells das coole ist, man
kann es nur richtig machen. Entweder kurzfristig
hohe Gewinne oder langfristig an einem der Top
Stammtellunternehmen zu profitieren. Weiß
jemand von Eúch ob ein größeres Unternehmen an
Stemcells beteiligt ist?

[aceman]

@TS80

Ja, Die Altana!

Gruß aceman

[LMeister7]

@ aceman
Guten Abend,
nobody is perfekt. Das muss ich übersehen haben. 2 Fragen deshalb: wo kann ich das nachlesen (Link) und wie gross ist die Beteiligung. Danke,
LM7

[LMeister7]

Hallo,
offensichtlich habe ich mich zu sehr auf die Angaben von Forbes, Whisper Earnings u. a. hinsichtlich der Quartals- und Jahreszahlen verlassen. In den letzten beiden Jahren, gab es diese Zahlen jeweils erst im April. Also müssen wir uns wohl noch etwas gedulden. Es sagt uns aber auch, dass wir nicht allen Angaben der einschlägigen Seiten blind vertrauen sollten.
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=STEM&…
In diesem Sinne,
LM7

[IngoBerndt]

Wann kommen denn jetzt die Zahlen von StemCells weiss denn keiner was?

[IngoBerndt]

Weiss denn eigentlich keiner wann Zahlen von Stemcells kommen.

[Bombenleger]

Press Release

SOURCE: StemCells, Inc.

StemCells, Inc. Reports Fourth Quarter and Year End 2001 Results

PALO ALTO, Calif., March 6 /PRNewswire-FirstCall/ -- StemCells, Inc. (Nasdaq: STEM - news) announced today financial
results for the fourth quarter and fiscal year ended December 31, 2001.

The Company reported a net loss of $3,524,000 or $0.15 per share, for the fourth quarter ended December 31, 2001, compared
to a net loss of $6,260,000, or $0.30 per share, for the fourth quarter of 2000. For the fiscal year ended December 31, 2001, the
Company reported a net loss of $3,446,000 or $0.15 per share applicable to common shareholders before deemed dividends, as
compared to a net loss of $11,125,000 or $0.57 per share, for the 2000 fiscal year. The net loss after deemed dividends for fiscal
year 2001 is $4,190,000 or $0.19 per share applicable to common shareholders, as compared to a net loss of $11,606,000 or
$0.58 per share, for the 2000 fiscal year. Total revenue for 2001 was $805,000, compared with $74,000 in 2000. Revenue for
2001 was from grants and assignment of rights to technology, while revenue for 2000 was from collaborative agreements. Cash,
and cash equivalents, were $13,697,000 at the end of 2001, compared with $6,069,000 at the end of 2000.

The decrease in net loss from 2000 to 2001 was attributed primarily to a realized gain on the sale of StemCells` remaining holdings
in Modex Therapeutics, offset by an increase in operating expenses due to the expansion of the Company`s research and
development activities.

``StemCells continued to make progress in 2001 with its proprietary technologies for the identification, purification and expansion
of adult stem cells derived from human organ tissue,`` said Martin McGlynn, the Company`s president and CEO. ``The first of the
Company`s proprietary organ-derived stem cells, the human neural stem cell, has been shown to not only survive transplantation,
but to give rise to the robust production of mature neural cells in small animal models. In 2001, we established multiple master cell
banks, containing highly purified and well-characterized human neural stem cells for use in our recently initiated pre-clinical testing
program in animal models of central nervous system disease. We were also happy to report the award of two significant multi-year
grants by the National Institutes of Health for our human liver stem cell discovery program.``

StemCells Inc. is a biotechnology company focused on the discovery, development and commercialization of stem cell-based
therapies to treat diseases of the central nervous system, liver and pancreas. The company`s stem cell programs seek to repair or
repopulate neural or other tissue that has been damaged or lost as a result of disease or injury.

Apart from statements of historical facts, the text of this press release constitutes forward-looking statements regarding, among
other things, the future business operations of StemCells, Inc. (``the Company``). The Company`s actual results may vary materially
from those contemplated in the forward-looking statements due to risks and uncertainties to which the Company is subject,
including uncertainties regarding the Company`s ability to obtain the capital resources needed to conduct the research, preclinical
development and clinical trials necessary for regulatory approvals; the fact that the Company`s stem cell technology is at the
pre-clinical stage and has not yet led to the development of any proposed product; the uncertainty whether the Company will achieve revenues from product sales or
become profitable; and other factors that are described in Exhibit 99 to the Company`s Annual Report on Form 10-K entitled ``Cautionary Factors Relevant to
Forward Looking Statements.``

SOURCE: StemCells, Inc.